Conference Reports for NATAP

Renal Conf: ELBASVIR/GRAZOPREVIR TREATMENT OF HCV INFECTION IN PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 4/5: CLINICAL, VIROLOGIC, AND HEALTH-RELATED QUALITY OF LIFE OUTCOMES IN THE C-SURFER STUDY       Reported by Jules Levin 53rd ERA-EDTA Congress in 2016, 53rd Congress of the European Renal Association May 21-24 Vienna, Austria   A Bruchfeld, D Roth, P Martin, D R Nelson, S Pol, M-C Londoño, S Wan, J M Arduino, M Robertson, B-Y Nguyen, J Wahl, E Barr, W Greaves   "HCV infection in patients with advanced chronic kidney disease is associated with an increased risk of death, accelerated loss of remaining kidney function and kidney transplant failure1-3 -Patients with HCV and stage 4/5 CKD have limited HCV treatment options due to lack of safety/efficacy data for DAAs in patients with CrCl <30mL/min and poor tolerability of regimens that include ribavirin" [from Jules: the earliest possible HCV treatment should be provided, delaying therapy can only increase risk for extra hepatic manifestations/comorbidities including kidney disease and increased risk for liver cancer (HCC). Medicaid & commercial therapy restrictions can be very harmful.]